NIH – Trans-Agency Blood-Brain Interface Program (R61/R33 – Clinical Trials Not Allowed)

September 10, 2019 by


This Funding Opportunity Announcement (FOA) will support high risk/high reward research on the blood/vascular component and regulation of the neurovascular blood unit (aka. Blood-Brain Barrier; BBB) in normal and pathological states to stimulate the development of a new field of science and re-define the neurovascular unit to also include the blood/vascular component to identify targets for diagnostics and regulation of the Blood-Brain Interface.


To date, the role of blood in the Blood-Brain Interface (e.g., blood-derived factors, blood-based biomarkers, circulating exosomes) in the pathogenesis of neurological disorders and brain injury states (e.g., brain trauma, stroke, amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer’s Disease) and the underlying neurovascular mechanisms remain largely unknown and under-researched. A trans-agency workshop on the blood–brain interface (BBI), sponsored by the National Heart, Lung and Blood Institute, the National Cancer Institute, and the Department of Defense Joint Program Committee-6 (JPC-6), Combat Casualty Care Research Program, was conducted in Bethesda MD on June 7-8, 2016. The presentations and discussions at the workshop underscored the role of the BBI in brain injury, as well as the role of the BBB as both a limiting factor and a potential conduit for drug delivery to the brain. At the conclusion of the meeting, the participants discussed challenges and opportunities confronting BBI translational researchers. In particular, the participants recommended using BBI translational research to stimulate advances in diagnostics, as well as targeted delivery approaches for detection and therapy of both brain injury and disease. This program announcement aims to address the recommendations from the 2016 Trans-Agency Blood-Brain Interface Workshop.

NHLBI intends to commit total costs of up to $1,100,000 in FY 2020, $4,400,000 in FY 2021, $4,400,000 in FY 2022, $4,400,000 in FY 2023, $4,400,000 in FY 2024 and $3,300,000 in FY 2025.

The Department of Defense Joint Program Committee-6 (JPC-6), Combat Casualty Care Research Program (CCCRP) intends to commit total costs of up to $2,200,000 per year in Fiscal Years 2020, 2021, 2022, 2023, and 2024.

Up to 5 new awards are expected to be funded in FY2020, and up to 5 new awards in FY 2021, for a total of up to 10 new awards.

Key Dates

Posted Date: September 3, 2019
Open Date (Earliest Submission Date): September 17, 2019
Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date(s): December 2, 2019, October 19, 2020

Web-link for more information:

Filed Under: Funding Opportunities